Inactive Instrument

Shandong Jintai Group Co., Ltd.

600385

CNE0000018K3

Shandong Jintai Group Co., Ltd. cancelled the transaction announced on March 4, 2021

June 26, 2022

On June 27, 2022, Shandong Jintai Group Co., Ltd. cancelled the transaction. The cancellation has been approved in the twenty fifth meeting of the tenth directorate and thirteenth meeting of the tenth supervisory board.

Latest news about Shandong Jintai Group Co., Ltd.

Shandong Jintai Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-25	CI
Shandong Jintai Group Co., Ltd. cancelled the transaction announced on March 4, 2021	22-06-26	CI
Shandong Jintai Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-28	CI
Shandong Jintai Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-28	CI
Shandong Jintai Group Co., Ltd. Auditor Raises 'Going Concern' Doubt	22-04-27	CI
Shandong Jintai Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-28	CI
Shandong Jintai Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-25	CI
Shandong Jintai Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-23	CI
Shandong Jintai Group Co., Ltd. announced that it expects to receive CNY 155.956825 million in funding from Beijing Towercrest Investment Management Group Co., Ltd	21-03-03	CI
Shandong Jintai Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020	20-10-28	CI
Shandong Jintai Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020	20-08-21	CI
Shandong Jintai Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-04-21	CI
Shandong Jintai Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2019	20-04-21	CI
Shandong Jintai Group Co., Ltd. Provides Earnings Guidance for the Year 2019	20-01-22	CI
Shandong Jintai Group Co., Ltd. completed the acquisition of Jinan Jinda Pharmaceutical Chemical Co., Ltd. from Beijing Towercrest Investment Management Group Co., Ltd.	19-12-15	CI
Jinan Jintai Pharmaceutical Technology Development Co., Ltd. announced that it expects to receive $12 million in funding from Shandong Jintai Group Co., Ltd.	19-11-07	CI
Shandong Jintai Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2019	19-10-29	CI
Shandong Jintai Group Co., Ltd. signed the share acquisition framework agreement to acquire Jinan Jinda Pharmaceutical Chemical Co., Ltd. from Beijing Towercrest Investment Management Group Co., Ltd. for CNY 80 million.	19-09-27	CI
Shandong Jintai Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2019	19-08-20	CI
Shandong Jintai Group Co., Ltd. cancelled the acquisition of Fujian Meinkind Baby Products Co., Ltd. from 18 shareholders.	19-08-07	CI
Shandong Jintai Group Co., Ltd. Announces Earnings Results for the Year 2018	19-04-23	CI
Shandong Jintai Group Co., Ltd. Announces Earnings Results for the First Quarter of 2019	19-04-23	CI
Shandong Jintai Group Plans To Buy Stake In FUJIAN MEINKIND	19-02-12	CI
Shandong Jintai Group Co., Ltd. entered into a framework agreement to acquire Fujian Meinkind Baby Products Co., Ltd. from 18 shareholders.	19-02-11	CI
Shandong Jintai Group Co., Ltd. Announces Earnings Guidance for the Full Year 2018	19-01-29	CI

Chart Shandong Jintai Group Co., Ltd.

Duration

Period

More charts

Company Profile

SHANDONG JINTAI GROUP CO., LTD. is a China-based company primarily engaged in the trading business of gold jewelry products. In addition, the Comapany is also engaged in the manufacture of drugs. The Company distributes its products within domestic market and to overseas markets.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals